Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

普罗米修斯CETR的总体目标是发现和开发基于人类抗体的预防和治疗药物，以对抗导致严重人畜共患病的两大类A类优先病毒-奈罗病毒克里米亚-刚果出血热病毒(CCHFV)，以及汉坦病毒安第斯病毒(ANDV)、辛诺布雷病毒(SNV)和普穆拉病毒(PUUV)。CCHFV、ANDV和SNV是对国家安全和公共卫生构成最高风险的A类代理人。在其最新的年度审查中，世界卫生组织将CCHF指定为蓝图优先疾病，最有可能导致公共卫生紧急情况。目前还没有针对这些制剂的疫苗或治疗方法。普罗米修斯CETR是来自学术界、政府和行业的七个合作伙伴之间的相互交织的合作，分为两个项目和三个核心，将实现两个宏伟目标，每个目标都旨在提供针对我们目标病毒病原体的治疗产品。我们将开发和提供：(1)基于抗体的疗法，对CCHFV具有广泛的疗效；(2)基于抗体的疗法，对汉坦病毒、汉坦病毒和新城疫病毒具有广泛的疗效。

The overarching goal of the Prometheus CETR is to discover and develop human antibody-based prophylactics and therapeutics against two major groups of Category A priority viruses that cause severe zoonotic disease—the nairovirus Crimean-Congo hemorrhagic fever virus (CCHFV), and the hantaviruses Andes virus (ANDV), Sin Nombre virus (SNV), and Puumula virus (PUUV). CCHFV, ANDV, and SNV are Category A agents that pose the highest risk to national security and public health. In their latest annual review, the World Health Organization designated CCHF as a Blueprint Priority Disease with the greatest potential to cause a public health emergency. There are no approved vaccines or treatments for any of these agents. The Prometheus CETR, an interwoven collaboration among seven partners from academia, government, and industry organized into two projects and three cores, will accomplish two Grand Goals that are each aimed at delivering a therapeutic product against our target viral pathogens. We will develop and deliver: (1) an antibody-based therapeutic with broad efficacy against CCHFV; and (2) an antibody-based therapeutic with broad efficacy against the hantaviruses ANDV and SNV.